---
title: "Viracta Therapeutics (VIRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VIRX.US.md"
symbol: "VIRX.US"
name: "Viracta Therapeutics"
industry: "Biotechnology"
datetime: "2026-05-20T22:22:04.982Z"
locales:
  - [en](https://longbridge.com/en/quote/VIRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VIRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VIRX.US.md)
---

# Viracta Therapeutics (VIRX.US)

## Company Overview

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company’s lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company’s product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.01 | 71 | - | - | - |
| PB | -0.06 | 499 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VIRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VIRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VIRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VIRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**